HK1211213A1 - Treatment of diseases involving mucin - Google Patents

Treatment of diseases involving mucin

Info

Publication number
HK1211213A1
HK1211213A1 HK15112050.5A HK15112050A HK1211213A1 HK 1211213 A1 HK1211213 A1 HK 1211213A1 HK 15112050 A HK15112050 A HK 15112050A HK 1211213 A1 HK1211213 A1 HK 1211213A1
Authority
HK
Hong Kong
Prior art keywords
treatment
diseases involving
involving mucin
mucin
diseases
Prior art date
Application number
HK15112050.5A
Other languages
English (en)
Chinese (zh)
Inventor
David L Morris
Roger Aston
Javed Akhter
Krishna Pillai
Original Assignee
Pitney Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012905519A external-priority patent/AU2012905519A0/en
Application filed by Pitney Pharmaceuticals Pty Ltd filed Critical Pitney Pharmaceuticals Pty Ltd
Publication of HK1211213A1 publication Critical patent/HK1211213A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22Cysteine endopeptidases (3.4.22)
    • C12Y304/22032Stem bromelain (3.4.22.32)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22Cysteine endopeptidases (3.4.22)
    • C12Y304/22033Fruit bromelain (3.4.22.33), i.e. juice bromelain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
HK15112050.5A 2012-12-17 2015-12-07 Treatment of diseases involving mucin HK1211213A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012905519A AU2012905519A0 (en) 2012-12-17 Treatment of diseases involving mucin
PCT/AU2013/001474 WO2014094041A1 (en) 2012-12-17 2013-12-17 Treatment of diseases involving mucin

Publications (1)

Publication Number Publication Date
HK1211213A1 true HK1211213A1 (en) 2016-05-20

Family

ID=50977393

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112050.5A HK1211213A1 (en) 2012-12-17 2015-12-07 Treatment of diseases involving mucin

Country Status (14)

Country Link
US (2) US11369666B2 (es)
EP (1) EP2931296B1 (es)
JP (1) JP6502853B2 (es)
KR (1) KR102255753B1 (es)
CN (2) CN104968358B (es)
AU (3) AU2013362878B2 (es)
CA (1) CA2895149C (es)
DK (1) DK2931296T3 (es)
ES (1) ES2727686T3 (es)
HK (1) HK1211213A1 (es)
NZ (1) NZ631536A (es)
TR (1) TR201907858T4 (es)
WO (1) WO2014094041A1 (es)
ZA (1) ZA201503979B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011670A1 (en) 2015-07-16 2017-01-19 Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center Compositions and methods for treating peritoneal cancers
WO2017063023A1 (en) * 2015-10-14 2017-04-20 Newsouth Innovations Pty Limited Compositions and methods for the treatment of diseases involving mucin
JPWO2017195792A1 (ja) * 2016-05-13 2019-03-14 国立大学法人 熊本大学 新規なpeg修飾酵素及びそれを用いた抗がん剤デリバリー
CN108066413A (zh) * 2016-11-15 2018-05-25 李雁 标准桃金娘油的癌性黏液溶解作用及抗肿瘤新用途
US20210008180A1 (en) * 2018-02-23 2021-01-14 MUCPharm Pty Ltd Formulations containing mucin-affecting proteases
BR112021017710A2 (pt) 2019-03-07 2021-11-16 Conatus Pharmaceuticals Inc Composto, composição farmacêutica, método de tratamento
US20230241188A1 (en) * 2020-05-01 2023-08-03 MUCPharm Pty Ltd Preventing and treating viral infections
CA3236057A1 (en) * 2021-10-27 2023-05-04 David Morris Methods for treating respiratory diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
DE4302060A1 (de) * 1993-01-26 1994-07-28 Mucos Pharma Gmbh & Co Verwendung von Bromelain zur Krebstherapie und/oder Metastasen-Prophylaxe
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH08337532A (ja) * 1995-06-14 1996-12-24 Takeda Chem Ind Ltd 医薬組成物
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
CH695414A5 (de) * 2001-05-30 2006-05-15 Guenter Holzner Kosmetische Präparate gegen die Alterung der menschlichen Haut in einer Mehrkammer-Mischpackung.
US6517832B1 (en) * 2001-08-24 2003-02-11 Jeffrey L. Marrongelle Formulations and methods for treating chronic migraine
BRPI0416877A (pt) * 2003-11-26 2007-02-06 Hills Pet Nutrition Inc método para reduzir odor de fezes de um animal doméstico
JPWO2006038315A1 (ja) * 2004-10-07 2008-07-31 株式会社サンギ 経皮・経粘膜吸収製剤
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US20080075710A1 (en) 2006-09-25 2008-03-27 Liquid Potions Llc Herbal composition for treating hangovers
US20100166726A1 (en) * 2007-03-07 2010-07-01 Northeastern University Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation
TWI461193B (zh) * 2009-07-24 2014-11-21 Taipei Veterans General Hospital 水飛薊或水飛薊賓用於治療神經受損之用途
JP5614978B2 (ja) * 2009-12-22 2014-10-29 独立行政法人農業・食品産業技術総合研究機構 穀物由来のプロアントシアニジン含有抽出物、及びその製造方法
CN103285383B (zh) * 2013-06-03 2015-01-07 海南通用同盟药业有限公司 一种包含菠萝蛋白酶的药物组合物及菠萝蛋白酶肠溶片

Also Published As

Publication number Publication date
JP6502853B2 (ja) 2019-04-17
CN116077631A (zh) 2023-05-09
US20150343035A1 (en) 2015-12-03
AU2013362878B2 (en) 2017-03-30
ES2727686T3 (es) 2019-10-17
DK2931296T3 (da) 2019-06-03
WO2014094041A1 (en) 2014-06-26
NZ631536A (en) 2016-12-23
AU2013362878A1 (en) 2015-06-18
EP2931296B1 (en) 2019-02-27
JP2016502981A (ja) 2016-02-01
CN104968358A (zh) 2015-10-07
KR102255753B1 (ko) 2021-05-26
EP2931296A4 (en) 2016-08-10
KR20150096445A (ko) 2015-08-24
ZA201503979B (en) 2017-11-29
US20220401529A1 (en) 2022-12-22
TR201907858T4 (tr) 2019-06-21
EP2931296A1 (en) 2015-10-21
US11369666B2 (en) 2022-06-28
AU2017204436B2 (en) 2019-05-30
AU2017204436A1 (en) 2017-07-20
CA2895149C (en) 2023-08-22
AU2019203315A1 (en) 2019-05-30
CA2895149A1 (en) 2014-06-26
CN104968358B (zh) 2022-11-18

Similar Documents

Publication Publication Date Title
HK1207574A1 (en) Treatment of myelosuppression
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
IL261659A (en) Brain cancer treatment
EP2906208A4 (en) THERAPEUTIC TREATMENT
HK1211213A1 (en) Treatment of diseases involving mucin
GB201506561D0 (en) Treatment of amblyopia
HK1214128A1 (zh) 癌症的治療
HK1204573A1 (en) Treatment of inflammatory skin disorders
HK1205254A1 (en) Methods of treatment of cancer
ZA201500547B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
GB201217892D0 (en) Treatment of cancer
HK1204956A1 (en) Treatment of cancer
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
GB201207907D0 (en) Treatment of depression
GB201217890D0 (en) Treatment of cancer
AU2012905519A0 (en) Treatment of diseases involving mucin
GB201204645D0 (en) Treatment of disease
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201218263D0 (en) Treatment of autism